BLRX
$3.50
Biolinerx
$.17
5.11%
BLRX
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  $0.00
Revenue:  N/A
Tuesday
Feb 23
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BLRX reports earnings?
Beat
Meet
Miss

Where is BLRX's stock price going from here?
Up
Flat
Down
Stock chart of BLRX
Analysts
Summary of analysts' recommendations for BLRX
Score
Grade
Pivots
Resistance
$4.34
$3.96
$3.65

$3.27

Support
$2.96
$2.58
$2.27
Tweet
Growth
Description
Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.